welcome
Investor's Business Daily

Investor's Business Daily

Business

Business & Economics

Multiple sclerosis biotech firm TG Therapeutics is a standout in the weakening stock market

Investor's Business Daily
Summary
Nutrition label

74% Informative

Multiple sclerosis biotech firm TG Therapeutics (TGTX) is a standout in the weakening stock market environment.

TGTX stock's latest breakout from an irregular base progressed Monday after two recent attempts had faded, despite a massive market sell-off.

The biotech firm makes a multiple sclerosis treatment named Briumvi , which is sold in the U.S. and Europe .

VR Score

75

Informative language

81

Neutral language

4

Article tone

formal

Language

English

Language complexity

37

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

detected

Known propaganda techniques

not detected

Time-value

short-lived

Affiliate links

no affiliate links